Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Dementia Congress 2019


Track 1: Dementia

Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Other common symptoms include emotional problems, problems with language, and a decrease in motivation. A person's consciousness is usually not affected. A dementia results in a change from a person's usual mental functioning and a greater decline than one would expect due to aging. These diseases also have a significant effect on a person's caregivers

Track 2:  Alzheimers disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia. The most common early symptom is difficulty in remembering recent events short-term memory loss. [As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioural issues. As a person's condition declines, they often withdraw from family and society.  Gradually, bodily functions are lost, ultimately leading to death.

Track 3: Vascular Dementia

Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. This death of brain cells can cause problems with memory, thinking or reasoning. Together these three elements are known as cognition. When these cognitive problems are bad enough to have a significant impact on daily life, this is known as vascular dementia.

Track 4: Frontotemporal dementia

Frontotemporal dementia is an uncommon type of dementia that mainly affects the front and sides of the brain (frontal and temporal lobes) and causes problems with behaviour and language. Dementia mostly affects people over 65, but front temporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, Frontotemporal dementia tends to develop slowly and get gradually worse over several years. Frontotemporal dementia is misdiagnosed as a psychiatric problem or as Alzheimer's disease.

Track 5: Neurodegenerative Diseases

Neurodegenerative diseases cause your brain and nerves to deteriorate over time. They can change your personality and cause confusion. They can also destroy your brain’s tissue and nerves. Some brain diseases, such as Alzheimer’s disease, may develop as you age. They can slowly impair your memory and thought processes. Other diseases, such as Tay-Sachs disease, are genetic and begin at an early age.

Track 6:  Brain diseases

The brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic injury.

Track 7: Parkinson’s diseases

Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Track 8: Anxiety & Depression

Apathy, depression and anxiety are common conditions experienced by people with dementia. They are known as psychological conditions because they can affect a person’s emotional and mental health. Anxiety is more than just feeling stressed or worried. Anxious feelings are a normal reaction to a situation where a person feels under pressure and usually pass once the stressful situation has passed, or the ‘stressor’ is removed. Depression affects how a person feels about themselves. A person may lose interest in work, hobbies and doing things he or she normally enjoys. Some people may lack energy, have difficulty sleeping or sleep more than usual, while some people feel anxious or irritable and find it hard to concentrate.

Track 9: Animal Models in Dementia

Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development have been carried out. Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development has been carried out.

Track 10: Amyloid protein in dementia

Amyloid Plaques One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP)

Track 11: Diagnosis of dementia

Diagnosing dementia and determining what type it is can be challenging. A diagnosis of dementia requires that at least two core mental functions be impaired enough to interfere with daily living. They are memory, language skills, ability to focus and pay attention, ability to reason, solve problem and visual perception

 Track 12: Nursing care in Dementia

Nurses provide the specialist dementia support that families need. When things get challenging or difficult, our nurses work alongside people with dementia, and their families: giving them one-to-one support, expert guidance and practical solutions.

Track 13: Dementia Management

There is no cure for dementia, so the chief goals of treatment are to:

a. Maintains quality of life

b. Enhances cognition, mood and behavior

c. Fosters a safe environment

d. Promotes social engagement

Track 14: Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Track 15: Recent Advancement in Treatments of Dementia

Epidemiological studies show that, worldwide, the number of people aged over 65 will increase substantially in the next decades and that a considerable proportion of this population will develop dementia. Ample evidence shows that ageing is associated with a high rate of painful conditions, irrespective of cognitive status. The number of patients with dementia who will experience painful conditions is therefore likely to increase.

Track 16: Clinical Trials & Case Reports in Dementia

The goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.

About Conference

After the successful completion of 12th World Congress on Advances and Innovations in Dementia we take the opportunity to announce. Dementia congress 2019, 13th World Congress on Advances and Innovations in Dementia, which is held during May 22-23, 2019 at Tokyo Japan. The main theme of our conference is "Exploring the Challenges and Excellence in Dementia Research" which covers wide range of critically important sessions. It’s a platform to bring all the neuroscientists together to share their experiences it’s the amalgam of scientific research as well as innovative ideas.

Neurological disorders are diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer's diseasebrain tumours, epilepsy, Parkinson's disease, and stroke, dementia as well as less familiar ones such as front temporal dementia.

In the present day scenario a wide population of mankind are plagued by mental and neurological illnesses, with almost 165 million people or 38 percent of the population suffering each year from a brain disorder. With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden, it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year. An estimated 6.8 million people die every year as a result of neurological disorders.

Neurological disorders public health challenges describes and discusses the increasing global public health importance of common neurological disorders such as dementia, epilepsy, headache disorders, multiple sclerosis, neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, stroke and traumatic brain injuries.

National Alliance provided fund of $650 million to fuel the research on mental illness. NARSAD Young Investigator Grant provides $30,000 per year on research in Neural and behavior disorders such as dementia, schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. Brain tumor research receives less than 1% (0.7%) of national cancer research spending in the UK.

 In order to accelerate the research in the field of Neuroscience Conference Series organizes different conference series worldwide.

About Organization

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference
  • Unique Opportunity! Online visibility to the Speakers and Experts




Vascular Dementia

Alzheimers disease

Neurodegenerative Diseases

Brain diseases

Animal Models in Dementia

Amyloid protein in dementia

Diagnosis of Dementia

Nursing care in Dementia

Dementia Management

Drug Development in Dementia

Recent Advancement in Treatments of Dementia

Clinical Trials & Case Reports in Dementia

Aging and Progressive dementia


 Who should attend?

  • Neuroscientist
  • Neuroanatomist
  • Neurobiologist
  • Neurochemist
  • Neurological Surgeon
  • Neurologist
  • Neuropathology’s
  • Neuropharmacologist
  • Neurophysiologist
  • Neuropsychologist
  • Neuroradiology’s
  • psych biologist
  • Biological Psychologist
  • Psychiatrist
  • Neuroscience Nurse
  •  Psychophysicist
  •  Professors
  •  Students
  •  Neuro drug Manufacturers

Benefits of attending:

  • Networking Opportunities
  • Grow Your Professional Network
  • Build Your Knowledge Base
  • Expand Your Resources
  • Meet Experts & Influencers Face to Face
  • Learning In a New Space
  • Break Out of Your Comfort Zone
  • New Tips & Tactics
  • Greater Focus
  • The Serendipity of the Random Workshop

Who should sponsor/exhibit:

  • Pharmaceuticals
  • Drug Manufacturers
  • Hospitals
  • Educational Institutes
  • Research Centres
  • Hospitals
  • Associations
  • Societies

Market Analysis

Theme: Exploring the Challenges and Excellence in Dementia Research

Dementia congress 2019 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the“13th World Congress on Advances and Innovations in Dementia” which is going to be held during May 22-23, 2019 Tokyo, Japan.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2019 organizing committee look forward to meeting you in Tokyo, Japan.

For more details please visit -

Why in Japan?

With one in five elderly Japanese predicted to have dementia by 2025, entire communities are working to improve the lives of older citizens and more 4.6 million people are living with dementia. And this number is expected to rise significantly as the population ages. Worldwide, at least 44 million people are living with dementia.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This numbers will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.

Major Neuroscience Societies and Associations in Tokyo:

World Federation of Neurology

Japanese Society of Child Neurology

Neurospinal Society of Japan

Cognitive Neuroscience Group


Major Dementia and Alzheimer’s Societies and Associations around Globe:

Alzheimer's Australia

Hilarescere Foundation in Italy

Alzheimer Society of Bangladesh

Alzheimer Support Group

Alzheimer's Association

Southern Clinical Neurological Society

American Academy of Neurology

ESNR European Society of Neuroradiology

European Neurological Societies

Alzheimer Austria

Foundation Alzheimer Aruba (FAA)

Alzheimer's disease Chinese

Spanish Society of Neurology

Alzheimer's Society

Major Neurological Associations in Italy

British brain tumor association


Top Neuroscience Universities in Japan

Aino University

Osaka Kawasaki Rehabilitation University

Hagoromo International University

Osaka University of Human Sciences

Hannan University

Soai University

Heian Jogakuin-St. Agnes'-University

Tokiwakai Gakuen University

Kansai Medical University

Osaka University

Kinki University

Okinawa Institute of Science and Technology

Kwansei Gakuin University, Osaka-Umeda

Keio University

Morinomiya University of Medical Sciences

Nagoya University

Top Neuroscience Universities in Globe:

Dalhousie University

University of Nottingham

Leiden University

Cardiff University

Temple University USA

University of Toronto

University Oklahoma

University Sheffield

University of Bristol

University California

Florida International University

University of Amsterdam

University of Edinburgh

Karolinska Institute

University of Milan

University of Gothenburg

Hospital Associated with Neuroscience:

Osaka University Hospital

Tokyo metropolitan neurological hospital

Kosei Nenkin Hospital

Shonan kamakura general hospital

Sumitomo Hospital

Jikei university school of medicine hospital

Yodogawa Christian Hospital

Yamaguchi university hospital

Wada Hospital

The university of tokyo hospital

Ueda Surgery Hospital

St. luke's international hospital

Osaka University Hospital

Japan bangladesh friendship hospital

Kosei Nenkin Hospital

Tokyo metropolitan neurological hospital


Companies Associated with Neuroscience in Japan


Forest Laboratories


Eli Lilly

Solvay of Belgium

Wyeth Pharmaceuticals

Fujisawa Pharmaceutical

Organon International

Meiji Seika

Lund beck

Janssen Pharmaceutical

Asahi Kasei Corporation

Top Neuroscience Companies:


Polyneuron Pharmaceuticals AG Corp.

reHaptix GmbH

Biogen Idec

KB Medical

Intento SA


AcelRx Pharmaceuticals, Inc.


AcelRx Pharmaceuticals, Inc.







Glance at market of dementia:-

There were an expected 46.8 million individuals overall living with dementia in 2015 and this number is accepted to be near 50 million individuals in 2017. This number will twofold at regular intervals, achieving 75 million out of 2030 and 131.5 million out of 2050. A great part of the expansion will be in creating nations. Officially 58% of individuals with dementia live in low and center pay nations, yet by 2050 this will ascend to 68%. The quickest development in the elderly populace is occurring in China, India, and their south Asian and western Pacific neighbors. The evaluated for the aggregate number of dementia sufferers worldwide in the years 2015, 2030 and 2050. It is evaluated that there will be around 75 million individuals experiencing dementia in 2030.

Statistic maturing is an overall procedure that demonstrates the achievements of enhanced human services in the course of the most recent century. Many are presently living longer and more beneficial lives thus the total populace has a more noteworthy extent of more seasoned individuals. Dementia principally influences more seasoned individuals, in spite of the fact that there is a developing familiarity with cases that begin before the age of 65. There are more than 9.9 million new instances of dementia every year around the world, inferring one new case at regular intervals.

The World Alzheimer Report 2015 updates ADI's worldwide assessments of the predominance, occurrence and expenses of dementia in view of efficient surveys. The report makes key suggestions to give a worldwide structure to activity on dementia. The report likewise incorporates a survey of the proof for and against late patterns in the predominance and frequency of dementia after some time, and in addition an examination of the more extensive societal effect of dementia. The aggregate assessed overall expense of dementia is US$818 billion of every 2015, which speaks to 1.09% of worldwide GDP. By 2018, the worldwide expense of dementia will transcend a US$ trillion.

Coordinate therapeutic consideration costs represent around 20% of worldwide dementia costs, while coordinate social area costs and casual consideration costs each record for about 40%. The relative commitment of casual consideration is most prominent in the African areas and least in North America, Western Europe and some South American districts, while the turnaround is valid for social part costs.  This implies if worldwide dementia care were a nation, it would be the eighteenth biggest economy on the planet.


Some products manufactured by the industry related Neuroscience Research:-

  •  NeuroScience ImmuWell.
  • NeuroScience AdreCor.
  • NeuroScience Calm CP.
  • Kavinace .
  • Purified anti-β-Dystroglycan Antibody.
  • Alexa Fluor® 594 anti-Neurofilament H (NF-H), Phosphorylated Antibody.
  • Mouse & Rat Spinal Cord Matrices.
  • Surgical & Dissection Tools. 

 Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease








Past Conference Report

Dementia Congress 2018

Past Conference Report


12th World Congress on Advances and Innovations in Dementia was organized during September 17-18, 2018 at Mercure Singapore on Stevens Singapore with the support and contribution of the Organizing Committee Members.

Firstly we must thank you for trusting us and participating at Dementia Congress 2018, a global platform to discuss various important aspects of Dementia.

There are infinite reasons to extend our gratitude to you for making the Dementia Congress 2018 outstanding conference. We couldn't have done it without your continuous support and believe towards our organization, which mutually made to achieve Dementia Congress 2018 a new heights in the field of Neuroscience.

The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 15 countries, who have driven this event into the path of success.   

The conference was organized around the theme “Exploring the Challenges and Excellence in Dementia Research”. The event implanted a firm relation of upcoming strategies in the field of Novel approaches and Developments in Dementia and Neurological disorders with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers: Harry S Goldsmith, University of California, USA; Michael Entzeroth, Chief Scientific Officer of Cennerv Pharma, Singapore

The conference witnessed an amalgamation of peerless speakers, Keynote speakers, well-known researchers and delegates who enlightened the crowd with their enviable research knowledge and on various alluring topics related to the field of Neuroscience through their fabulous presentations at the podium of Dementia Congress 2018.   

Conference series LLC offers its heartfelt appreciation to all the Organizing Committee Members, Chairs and Co-chairs, Speakers, Students, Media Partners, sponsors and Editorial Board Members of Journal of Alzheimers Disease & Parkinsonism, Journal of Dementia, Journal of Neurological Disorders, who supported the conference in every aspect for the awe-inspiring exhibition at the venue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Jerzy Leszek, Head Of Alzheimer’s Disease Lab, Wroclaw Medical University, Poland; Harry S Goldsmith, University of California, USA; Michael Entzeroth, Chief Scientific Officer of Cennerv Pharma, Singapore

So as a continuation of Dementia Congress 2018, we would like to heartily invite you to our upcoming 13th World Congress on Advances and Innovations in Dementia scheduled during May 22-23, 2019 at Tokyo, Japan.

For 2019 we are expanding our focus towards all aspects of Dementia  and Alzheimer’s Re­search findings. Our organizing committee is gearing up with more innovative and explorative sessions to unleash the boundaries of the Neuroscience.

Your expertise and knowledge in the area of Dementia and Alzheimer’s Will provide an oppor­tunity to discuss and respond to a series of questions about the status of Dementia AND Neurological Disorders and therapeutics.

There were an expected 46.8 million individuals overall living with dementia in 2015 and this number is accepted to be near 50 million individuals in 2017. This number will twofold at regular intervals, achieving 75 million out of 2030 and 131.5 million out of 2050. A great part of the expansion will be in creating nations. Officially 58% of individuals with dementia live in low and center pay nations, yet by 2050 this will ascend to 68%. The quickest development in the elderly populace is occurring in China, India, japan and their south Asian and western Pacific neighbours.

We would like to organize this conference with your support to gather all the Neuroscience researchers in an single platform, hope we will be honoured with your support to organize Neuroscience 2018 in a grand level, your support will be the key of success for our next year conference.

We look forward to see your benign presence with active contribution and support to make this event successful once more.

Once again it’s our pleasure to welcome you to our upcoming

13th World Congress on Advances and Innovations in Dementia

May 22-23, 2019 Tokyo, Japan

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date May 22-23, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Alzheimers Disease & Parkinsonism Journal of Dementia Journal of Neurology and Neuroscience

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by